NasdaqCM:IMNMBiotechs
Assessing Immunome (IMNM) Valuation After Phase 3 RINGSIDE Success and 2026 FDA Filing Plans
Immunome (IMNM) grabbed investor attention after revealing that its pivotal Phase 3 RINGSIDE trial for desmoid tumors hit both its primary and key secondary endpoints, setting up a potential US approval filing in 2026.
See our latest analysis for Immunome.
The upbeat RINGSIDE data has been the clear catalyst behind Immunome’s recent rally, with a 30 day share price return of 36.99 percent and a 90 day share price return of 161.18 percent helping drive a 3 year total shareholder return of...